If you’ve never had the chance to see Kaplan-Meier survival curves….

Check these out. They are survival curves from a successful clinical trial of treatments for metastatic squamous non–small-cell lung cancer. These beautifully-presented below graphs show both triumph and tragedy. The new therapy definitely extended survival. Yet the difference in median survival is only three months. A long way to go. And I’m so happy my friend quit smoking.

PS-RhodesKen is correct that the probability of two-year survival is notably better with the new therapy. That is very good news.

Overall survival benefit for patients treated with nivolumab vs. docetaxel

Comments

  1. RhodesKen says

    Harold, you comment "difference in median survival is only three months."

    But I see another difference, which seems very important. The Long Term Survival Rate (a loosely chosen term by me) seems to have doubled. That's gotta be good.

  2. Brett_Bellmore says

    Yeah, that's what drew my eye. Went from maybe 15% to 30% 'cure' rate. That's big.

    And, frankly, at the rate cancer research is advancing right now, even a few months can be significant.

  3. schmidtb98 says

    A close relative died 2 months ago from lung cancer (don't know if it's the same type as this).

    Three months more would be a gift to patients, especially if it's a good quality of life.

    • RhodesKen says

      Yes, my wife Pat died from precisely the type of cancer mentioned, three months after her initial diagnosis.

      Three extra months would have been a gift; six extra months would have been a miracle.

Leave a Reply

Your email address will not be published.

You may use these HTML tags and attributes: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <strike> <strong>